5-bromo-N-(3-methylpyridin-4-yl)thiophene-2-carboxamide | 1311877-17-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-bromo-N-(3-methylpyridin-4-yl)thiophene-2-carboxamide
• CAS: 1311877-17-4
• 化学式: C₁₁H₉BrN₂OS
• 分子量: 297.175
• InChiKey: RTFHMNGPDWUDSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-bromo-N-(3-methylpyridin-4-yl)thiophene-2-carboxamide 、 5-[6-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl]-3-methyl-1,3,4-oxadiazol-2(3H)-one 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 18.0h， 生成 5-(2-cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-N-(3-methylpyridin-4-yl)thiophene-2-carboxamide
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS
  [FR] COMPOSÉS SUBSTITUÉS DE PYRIDINE EN TANT QUE MODULATEURS DE CRAC

  摘要：

  本发明涉及式(I)描述的化合物以及其中医药可接受的盐，这些化合物能够调节钙释放激活钙(CRAC)通道的活性。该发明还描述了式(I)的化合物以及包含这些化合物的药物组合物，用于治疗、管理和/或减轻与调节钙释放激活钙(CRAC)通道相关联的疾病、障碍、综合征或状况的严重性。

  公开号：

  WO2013164769A1
• 作为产物：
  描述：

  5-溴噻吩-2-甲醛 在 N,N-二甲基甲酰胺 Jones reagent 、 草酰氯 、 sodium hydride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 、 mineral oil 为溶剂， 反应 7.0h， 生成 5-bromo-N-(3-methylpyridin-4-yl)thiophene-2-carboxamide
  参考文献：
  名称：

  [EN] OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS
  [FR] MODULATEURS DE CANAUX CRAC À BASE D'OXAZOLE ET D'ISOXAZOLE

  摘要：

  公开号：

  WO2012056478A8

文献信息

• SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20160145268A1

  公开（公告）日：2016-05-26

  The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CR 3 or N; Y is CR 3 or N; L is selected from —NR 2 C(O)—, —C(O)NR 2 — and —NR 2 CR a R b —; R a and R b are independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).

  该发明涉及式(I)的化合物及其药用可接受盐，其中取代基如本文所述，并且它们在医学上用于治疗与钙释放激活钙（CRAC）通道调节相关的疾病和紊乱。该发明还涉及含有这种化合物的药物组合物，用于治疗与钙释放激活钙（CRAC）通道调节剂相关的疾病和紊乱。其中，环D是式(a)或式(b)：A和B，可以相同也可以不同，分别独立地为CR3或N；Y为CR3或N；L选自—NR2C(O)—、—C(O)NR2—和—NR2CRaRb—；Ra和Rb独立地为氢、卤素或取代或未取代的烷基；环E选自式(i)至式(vii)。
• SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20150111900A1

  公开（公告）日：2015-04-23

  The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.

  本发明涉及描述为公式(I)的化合物及其药用可接受盐，其调节钙释放激活钙(CRAC)通道的活性。本发明还描述了公式(I)的化合物及含有该化合物的药物组合物，用于治疗、管理和/或减轻与调节钙释放激活钙(CRAC)通道相关的疾病、疾病、综合征或病症的严重程度。
• OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS
  申请人：Irlapati Nageswara Rao

  公开号：US20130225600A1

  公开（公告）日：2013-08-29

  The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

  本发明涉及式（I）的化合物及其制备方法，这些化合物对于治疗、预防和/或管理与CRAC调节相关的疾病、紊乱、综合症或状况是有用的。本发明还涉及使用式（I）的化合物治疗、预防、管理和/或减轻与CRAC调节相关的疾病、紊乱、综合症或状况的方法。
• Oxazoline and isoxazoline derivatives as CRAC modulators
  申请人：Irlapati Nageswara Rao

  公开号：US09169242B2

  公开（公告）日：2015-10-27

  The present invention relates to compounds that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC and to processes for preparing these compounds. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC by these compounds.

  本发明涉及用于治疗、预防和/或管理与CRAC调节相关的疾病、障碍、综合征或情况的化合物，并涉及制备这些化合物的过程。此外，本发明还涉及通过这些化合物治疗、预防、管理和/或减轻与CRAC调节相关的疾病、障碍、综合征或情况的方法。
• OXAZOLE AND ISOXAZOLE CRAC MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20160022673A1

  公开（公告）日：2016-01-28

  The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

  本发明涉及公式（I）的化合物及其制备方法，用于治疗、预防和/或管理与CRAC调节相关的疾病、疾病、综合征或病况。本发明还涉及使用公式（I）的方法来治疗、预防、管理和/或减轻与CRAC调节相关的疾病、疾病、综合征或病况。